Pharmaceuticals

Bausch Health

Bausch Health released FY2026 Q1 earnings on April 29 After-Market (EST), actual revenue USD 2.524 B (forecast USD 2.408 B), actual EPS USD -3.82 (forecast USD -0.83)

Bausch Health to Release FY2026 Q1 Earnings on April 29 After-Market EST, Forecast Revenue USD 2.408 B, EPS USD -0.815

Bausch Health released FY2025 Q4 earnings on February 18 After-Market EST, actual revenue USD 2.796 B (forecast USD 2.708 B), actual EPS USD -0.3 (forecast USD 0.4225)

Bausch Health released FY2025 Annual Earnings on February 18 After-Market EST, with forecasted revenue of USD 10.18 B and EPS of USD 1.21

Bausch Health to Release FY2025 Q4 Earnings on February 18, 2026 After-Market EST, Forecast Revenue USD 2.708 B, EPS USD 0.4225

Bausch Health's drug for hepatic encephalopathy trial fails to meet primary endpoint

Paulson &amp; Co. Cashes Out of Google C and Adds to Bausch Health

Bausch Health released FY2025 Q3 earnings on October 29 After-Market (EST), actual revenue USD 2.681 B (forecast USD 2.626 B), actual EPS USD 0.4766 (forecast USD 0.38)

Bausch Health released FY2025 9 Months Earnings on October 29 After-Market EST, actual revenue USD 7.47 B, actual EPS USD 0.7262

Bausch Health to Release FY2025 Q3 Earnings on October 29 After-Market EST, Forecast Revenue USD 2.619 B, EPS USD 0.36

Bausch Health Announces 5 Millionth Thermage Skin Tightening Treatment

Carl Icahn Exits Bausch Health Holding, Insiders Make Significant Buys

John Paulson Acquires Common Stock of Bausch Health Companies Inc.

Durect Corporation Extends Deadline for Bausch Health Merger Agreement

Bausch Reports Q2 2025 Earnings Decline and Revenue Growth

Bausch Health released FY2025 Semi-Annual Earnings on July 30 After-Market EST, with actual revenue of USD 4.789 B and EPS of USD 0.24

Bausch Health released FY2025 Q2 earnings on July 30 After-Market EST, actual revenue USD 2.53 B (forecast USD 2.485 B), actual EPS USD 0.399 (forecast USD 0.045)

Bausch Health Announces Acquisition of DURECT to Enhance Liver Disease Treatment Portfolio

Bausch Health Expects EPS of 94 Cents in Q2 2025

Bausch Health Announces $900 Million Debt Relief Plan

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

Analysts at Zacks Research have raised their Q2 2026 EPS estimate for Bausch Health Cos from $0.94 to $0.96. The full-year earnings estimate is $4.08 per share. Other analysts have varied ratings, with target prices ranging from $7.00 to $10.00. Bausch Health's stock opened at $5.32, with a market cap of $1.99 billion and a P/E ratio of -1.64. The company reported $0.78 EPS last quarter, missing estimates by $0.03.

Market Beat

Raymond James Financial

ROYAL BANK OF CANADA

Zoetis

CAITONG SECURITIES

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Q2 EPS Estimate for Bausch Health Cos Boosted by Analyst

Bausch Health Announces 2026 Annual Meeting of Shareholder Results | BHC Stock News

StockTitan

Bausch Health Announces 2026 Annual Meeting of Shareholder Results | BHC Stock News

Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference | BHC Stock News

Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference | BHC Stock News

Bausch Health Companies Inc. (NYSE:BHC) will participate in a fireside chat at the Barclays 30th Annual Leveraged Finance Conference on May 19, 2026, at 10:25 a.m. U.S. ET. A live audio webcast will be available on their Investor Relations website, with a replay accessible afterward. Bausch Health is a global pharmaceutical company focused on improving healthcare outcomes across various sectors. Forward-looking statements are included, cautioning against undue reliance on them.

Bausch + Lomb

Barclays

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference | BHC Stock News

CURLF

SHOP

The TSX Composite Index fell 71.06 points to 33,566.91, influenced by a drop in Shopify shares, which fell 15.6%. TMX Group reported better-than-expected earnings, while Dream Impact Trust's losses widened. Health-care stocks rose, with Curaleaf and Bausch Health gaining. The TSX Venture Exchange also declined. In the U.S., stocks surged, with the Dow up 356.63 points and the NASDAQ hitting an all-time high. Oil prices dropped, while gold prices increased significantly. Overall, 85% of S&P 500 companies exceeded earnings expectations.

Baystreet

Curaleaf Holdings, Inc.

Shopify 

Kinross Gold

ZHONGJIN GOLD

EFUND GOLD MI-U

Abrdn Gold ETF Trust

VALUEGOLD ETF

Direxion Daily Jr Gold Miners Bull 2X

SPDR S&P Health Equip

Sprott GLD Miners Etf

Us Gbl GLD & Met

ALPS Medical Breakthrough

Abrdn Precious Metals Basket ETF Trust

Direxion Daily SHOP Bear 1X ETF

EFUND GOLD MI-R

iShares US Medical Devices

iShares MSCI Global Gold Miners

SPDR Gold Minishares

ChinaAMC Gold ETF

iShares Gold Trust

VanEck Junior Gold Miners ETF

GLOBAL X Gold Explorers

VanEck Gold Miners ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Roundhill Gold Miners Weeklypay ETF

EFUND GOLD MI ETF

TSX Staggers by Tuesday Finish

Investors liked what they saw with the company's opening 2026 earnings report.

Why Bausch Health Companies was crawling higher this week

Bausch Health(BHC.US)

Q2 EPS Estimate for Bausch Health Cos Boosted by Analyst

Bausch Health Announces 2026 Annual Meeting of Shareholder Results | BHC Stock News

Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference | BHC Stock News

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference | BHC Stock News

TSX Staggers by Tuesday Finish

Why Bausch Health Companies was crawling higher this week